作为肺结核肺结核的宿主导疗法,Bcl-2 抑制剂作为宿主导疗法
Sanjay Jain1, Medha Singh1, Mona Sarhan1
1Johns Hopkins University School of Medicine.
Research square
|September 16, 2024
概括
一种Bcl-2抑制剂Navitoclax通过促进免疫细胞亡来增强结核病治疗. 这种宿主导疗法在小鼠模型中减少了细菌负载,组织损伤和纤维化.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
背景情况:
- 结核菌菌菌的感染导致宿主细胞通过Bcl-2蛋白质对细胞亡产生抵抗力,导致死亡,炎症和纤维化.
- 目前的结核病治疗可以通过针对宿主细胞通路的宿主导疗法来增强.
研究的目的:
- 评估Bcl-2抑制剂纳维托克拉克斯作为一种宿主导疗法,以改善肺结核病 (TB) 治疗结果.
- 评估纳维托克拉克斯对结核病小鼠模型中的细菌清除,组织损伤,纤维化和免疫细胞亡的影响.
主要方法:
- 在小鼠模型中与标准结核病治疗一起使用纳维托克拉克斯.
- 利用免疫组织化学和流动细胞计量来分析免疫细胞亡.
- 在活体动物中使用新生物标志物 (18F-ICMT-11用于细胞亡,18F-FAPI-74用于纤维化) 的正子发射断层扫描 (PET).
主要成果:
- 纳维托克拉克斯治疗显著改善了细菌清除,并减少了肺组织损伤和纤维化.
- 纳维托克拉克斯在CD68+和CD11b+免疫细胞中诱导了亡.
- PET成像显示肺组织中亡的增加和纤维化的减少,死后分析证实了这一点.
结论:
- 作为宿主导疗法,Navitoclax通过向宿主细胞亡来改善肺结核治疗的显著潜力.
- 诸如纳维托克拉克斯 (navitoclax) 这样的前性药物需要进一步的研究和临床试验,以加强结核病的治疗.
更多相关视频
相关概念视频
Pulmonary Tuberculosis V
172
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
172
Pulmonary Tuberculosis II
214
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
214
Pulmonary Tuberculosis I
225
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
225
Pulmonary Tuberculosis IV
134
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
134
Pulmonary Tuberculosis III
313
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
313
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


